TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26313291

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 161
Study: 25011604

Group type: EXPERIMENTAL
Intervention: Antibiotic mixing (9 months) using third- or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems during consecutive antibiotic courses.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Antibiotic cycling (9 months) using third- or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems during consecutive 6-week periods.
Number of subjects: 8
Study: 22189669

Group type: EXPERIMENTAL
Intervention: Intense resistance exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 10
Study: 20923715

Group type: EXPERIMENTAL
Intervention: Mobile van intervention
Number of subjects: 110432

Group type: COMPARATOR
Intervention: Door-to-door intervention
Number of subjects: 110432

Group type: EXPERIMENTAL
Intervention: Combined interventions
Number of subjects: 110432
Study: 18022845

Group type: EXPERIMENTAL
Intervention: Steady-state free-precession (SSFP) MRI
Number of subjects: 375

Group type: COMPARATOR
Intervention: Full MRI
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: SSFP
Number of subjects: 375
Study: 15864217

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 53
Study: 12834663

Group type: EXPERIMENTAL
Intervention: Posterior Chamber Intraocular Lens (PC IOL)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Anterior Chamber Intraocular Lens (AC IOL)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 438
Study: 11720758

Group type: EXPERIMENTAL
Intervention: MIP regimen (2 or 4 cycles) in perioperative setting
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (cisplatin based)
Number of subjects: 100
Study: 9167759

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (lomustine 80 mg/m2 day 1; carboplatin 80 mg/m2 days 1, 8, 15, 22; vinorelbine 20 mg/m2 days 1, 8, 15, 22; L-leucovorin 250 mg/m2 days 1, 8, 15, 22; fluorouracil 500 mg/m2 days 1, 8, 15, 22; cycles repeated every 6 weeks)
Number of subjects: 28
Study: 8271805

Group type: EXPERIMENTAL
Intervention: Cigarettes (substance type)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Alcohol (substance type)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Cocaine (substance type)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Treatment (recovery method)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Self-change (recovery method)
Number of subjects: 579
Study: 3515931

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Normal Volunteers
Number of subjects: 11

Group type: COMPARATOR
Intervention: Patients
Number of subjects: 11
Study: 31175909

Group type: EXPERIMENTAL
Intervention: brodalumab 210 mg every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: brodalumab 210 mg every 2 weeks after ustekinumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous brodalumab 210 mg every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safety through 120 weeks
Number of subjects: 0
Study: 29050498

Group type: EXPERIMENTAL
Intervention: Program A (no analgesics or acute migraine-medication)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Program B (acute medication restricted to two days/week)
Number of subjects: 72
Study: 27440499

Group type: EXPERIMENTAL
Intervention: Portable Video Media (PVM)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard Verbal Communication (SVC)
Number of subjects: 88
Study: 24796042

Group type: EXPERIMENTAL
Intervention: Triple-strong stimulation group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupuncture + medication group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (triple-strong stimulation, acupuncture, acupuncture + medication)
Number of subjects: 120
Study: 23081745

Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol (100/10 or 250/10 μg b.i.d.)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Fluticasone/salmeterol (100/50 or 250/50 μg b.i.d.)
Number of subjects: 202
Study: 19752761

Group type: EXPERIMENTAL
Intervention: Hormone therapy and atorvastatin (80 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Statin therapy (atorvastatin)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 19263677

Group type: EXPERIMENTAL
Intervention: Participative education (PE)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Traditional education (TE)
Number of subjects: 202
Study: 15914987

Group type: EXPERIMENTAL
Intervention: Fluoride gel application
Number of subjects: 773
Study: 12941201

Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiotherapy
Number of subjects: 556

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 556
Study: 16463756

Group type: EXPERIMENTAL
Intervention: support/work-planning intervention
Number of subjects: 151

Group type: COMPARATOR
Intervention: standard prenatal curriculum group
Number of subjects: 151
Study: 10188889

Group type: EXPERIMENTAL
Intervention: 30 mg beta-carotene
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: beta-carotene
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: vitamin C
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: both vitamins
Number of subjects: 141
Study: 7591527

Group type: EXPERIMENTAL
Intervention: Formula with long-chain polyunsaturated fatty acids (LCP-F)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Formula without LCP
Number of subjects: 32
Study: 2301715

Group type: COMPARATOR
Intervention: amikacin/metronidazole/placebo (Group 1, 56 patients)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: amikacin/clindamycin/placebo (Group 2, 57 patients)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: amikacin/clindamycin/ampicillin (Group 3, 43 patients)
Number of subjects: 156

Group type: COMPARATOR
Intervention: amikacin/metronidazole/placebo (Group 1, 13 patients post-exclusion)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: amikacin/clindamycin/placebo (Group 2, 45 patients post-exclusion)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Successful treatment outcomes (106 evaluable patients)
Number of subjects: 156
Study: 7447772

Group type: EXPERIMENTAL
Intervention: Retaining the lenses
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lensectomy
Number of subjects: 50
Study: 6150724

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29367324

Group type: EXPERIMENTAL
Intervention: Informed Health Choices (IHC) Key Concepts
Number of subjects: 0
Study: 29894608

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 68
Study: 25518180

Group type: EXPERIMENTAL
Intervention: Disclosed plaque visualization
Number of subjects: 122

Group type: COMPARATOR
Intervention: No disclosed plaque visualization (Control)
Number of subjects: 122
Study: 22211824

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 20195905

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Number of subjects: 4092
Study: 18190651

Group type: EXPERIMENTAL
Intervention: 2 L PEG + Asc
Number of subjects: 308

Group type: COMPARATOR
Intervention: 4 L PEG + E
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: PEG + Asc
Number of subjects: 308

Group type: COMPARATOR
Intervention: PEG + E
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: PEG + Asc and PEG + E
Number of subjects: 308
Study: 16175842

Group type: EXPERIMENTAL
Intervention: Family-supported intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinician-delivered intervention
Number of subjects: 0
Study: 12637904

Group type: EXPERIMENTAL
Intervention: 2-point expander
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4-point expander
Number of subjects: 30
Study: 10671603

Group type: EXPERIMENTAL
Intervention: Volume rendering with transition zone reconstructed separately from the wall
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Surface rendering with transition zone attenuation equal to wall attenuation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Surface rendering with transition zone attenuation equal to air attenuation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Surface rendering with transition zone attenuation halfway between air and wall
Number of subjects: 27
Study: 8836612

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 60 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 120 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 240 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1344880

Group type: EXPERIMENTAL
Intervention: Progesterone suppositories or oral dehydroprogesterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 3830804

Group type: EXPERIMENTAL
Intervention: 3-week chemotherapy regimen associated with whole abdominal radiotherapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Chemotherapy for 3 years
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone for 3 years (27 stage IIID and 36 stage IV patients)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, prednisone for low grade lymphomas (16 patients)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, adriamycin, prednisone for intermediate (56 patients) and high grade (10 patients) lymphomas
Number of subjects: 82
Study: 29866212

Group type: EXPERIMENTAL
Intervention: Intervention: Antipsychotic treatment (specifics not provided)
Number of subjects: 1136
Study: 30140963

Group type: EXPERIMENTAL
Intervention: 20 G vitrectomy plus encircling band (group E1)
Number of subjects: 163

Group type: COMPARATOR
Intervention: 20 G vitrectomy without any buckle (group C)
Number of subjects: 163
Study: 27560704

Group type: EXPERIMENTAL
Intervention: Extended sleep (EXT; time in bed: 2100‐0700 h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Habitual sleep (HAB; time in bed: 2230‐0700 h)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 24 hours of sleep deprivation
Number of subjects: 14
Study: 25436225

Group type: EXPERIMENTAL
Intervention: Scoliosis-specific exercise treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Observation regime (Control)
Number of subjects: 144
Study: 25453004

Group type: EXPERIMENTAL
Intervention: Propofol and Suxamethonium (PS)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Propofol and Lidocaine (PL)
Number of subjects: 88
Study: 20170514

Group type: EXPERIMENTAL
Intervention: 12 weeks of PEG‐IFN‐alpha-2a (180 ug/week) and ribavirin (800‐1200 mg/day)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 24 weeks of PEG‐IFN‐alpha-2a (180 ug/week) and ribavirin (800‐1200 mg/day)
Number of subjects: 210

Group type: COMPARATOR
Intervention: 24 weeks of PEG‐IFN‐alpha-2a and ribavirin (for patients without rapid virological response)
Number of subjects: 210
Study: 18325883

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 2295

Group type: COMPARATOR
Intervention: Non-ultrasound-guided embryo transfer
Number of subjects: 2295
Study: 15884127

Group type: EXPERIMENTAL
Intervention: Gastrografin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (200 mL of 5% dextrose water)
Number of subjects: 50
Study: 12882432

Group type: EXPERIMENTAL
Intervention: Prompting intervention (weekly telephone or mail-delivered cues)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Motivational intervention (3-encounter motivational sessions)
Number of subjects: 190
Study: 10673189

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 800 microg twice daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ozone exposure (400 ppb for 2 hours)
Number of subjects: 15
Study: 9119568

Group type: EXPERIMENTAL
Intervention: Preventive intervention study
Number of subjects: 1785
Study: 1503061

Group type: EXPERIMENTAL
Intervention: Supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsupplemented children
Number of subjects: 0
Study: 6662157

Group type: EXPERIMENTAL
Intervention: Prizidilol hydrochloride 400‐700 mg once daily (mean 612 mg/day)
Number of subjects: 14
Study: 30462939

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus R0011 and L. helveticus R0052) at a dose of 4.0×10^9 CFUs twice daily for 5 days
Number of subjects: 886

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 886
Study: 28317328

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body weight influence on dosage
Number of subjects: 0
Study: 26131783

Group type: COMPARATOR
Intervention: Simulators
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Live tissue
Number of subjects: 20
Study: 23968383

Group type: EXPERIMENTAL
Intervention: No prophylaxis during surgical procedures
Number of subjects: 331
Study: 20385300

Group type: EXPERIMENTAL
Intervention: Short loop group (SLG; n = 110)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Conventional group (CG; n = 108)
Number of subjects: 218
Study: 17996212

Group type: EXPERIMENTAL
Intervention: Topical levofloxacin (0.5%) four times on the day before surgery + Povidone-iodine (PVI) irrigation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Povidone-iodine (PVI) irrigation alone
Number of subjects: 140
Study: 16855194

Group type: EXPERIMENTAL
Intervention: Intervention with parental support group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intervention‐alone group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 12632137

Group type: EXPERIMENTAL
Intervention: 20 ml of 0.5% bupivacaine and 5 mg/ml epinephrine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 50
Study: 11195900

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy with irradiation and heating
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ultrasound therapy without irradiation or heating (placebo group)
Number of subjects: 35
Study: 9028977

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Extrapleural intercostal nerve block with intermittent low-dose bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 30
Study: 1504638

Group type: EXPERIMENTAL
Intervention: Intermittent nicotine (15 mu/kg) via nasal spray
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nicotine or smoking
Number of subjects: 42
Study: 6408940

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pheniramine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Safety evaluation (blood tests)
Number of subjects: 51
Study: 30826693

Group type: EXPERIMENTAL
Intervention: Promotion focused orientation
Number of subjects: 2064

Group type: EXPERIMENTAL
Intervention: Present hedonistic perspective
Number of subjects: 2064

Group type: EXPERIMENTAL
Intervention: Internal locus of control
Number of subjects: 2064

Group type: EXPERIMENTAL
Intervention: Sensation seeking
Number of subjects: 2064
Study: 30419038

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy for social activation (CBTsa)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 99
Study: 26504778

Group type: EXPERIMENTAL
Intervention: Multistep dissemination strategy
Number of subjects: 1627

Group type: COMPARATOR
Intervention: Brochure only dissemination strategy
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Monothematic dissemination strategy
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Comprehensive dissemination strategy
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Worksite tobacco prevention measures
Number of subjects: 1627
Study: 23867242

Group type: EXPERIMENTAL
Intervention: Qigong intervention (1 hour, twice per week for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 30
Study: 22944289

Group type: EXPERIMENTAL
Intervention: Pancreatic duct stenting (3-5Fr, 5-7cm long), removed endoscopically 1-2 weeks post-ERCP
Number of subjects: 191

Group type: COMPARATOR
Intervention: No pancreatic duct stenting (no-stent group)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Pancreatic duct stenting
Number of subjects: 191

Group type: COMPARATOR
Intervention: No pancreatic duct stenting
Number of subjects: 191
Study: 19302903

Group type: EXPERIMENTAL
Intervention: Single-dose oral SAMe (1000 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single-dose IV SAMe (1000 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multiple-dose oral SAMe (1000 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multiple-dose IV SAMe (1000 mg)
Number of subjects: 20
Study: 17825690

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate/fluticasone propionate (SFC) hydrofluoroalkane metered-dose inhaler (MDI) at 25/50 microg/actuation (group 1), 25/125 microg/actuation (group 2), or 25/250 microg/actuation (group 3), administered as 2 inhalations BID for 52 weeks.
Number of subjects: 325
Study: 15131679

Group type: EXPERIMENTAL
Intervention: Intervention practices (training in optic disc assessment, explicit referral criteria, and ophthalmologist feedback)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 397
Study: 11725825

Group type: EXPERIMENTAL
Intervention: 30 mg cisapride orally three times daily for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (20 age-matched controls)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 30
Study: 9922587

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 MU over 1 hour)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: rt-PA (100 mg in 1.5 hours)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: TNK-t-PA (30-40 mg in 15 s)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no thrombolysis)
Number of subjects: 29
Study: 9121623

Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.08 mg nicotine yield
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.17 mg nicotine yield
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.37 mg nicotine yield
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.48 mg nicotine yield
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.74 mg nicotine yield
Number of subjects: 32
Study: 2156649

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg) administered daily for 7 days after pretreatment with 1,25-dihydroxyvitamin D
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg) administered daily for 7 days with placebo pretreatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Acetazolamide (500 mg) administered daily for 7 days to normal control subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg) administered daily for 7 days after pretreatment with placebo
Number of subjects: 36
Study: 113129

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 384

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Surgical treatment with all grafts patent
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Surgical treatment with all grafts closed
Number of subjects: 384
Study: 31706315

Group type: EXPERIMENTAL
Intervention: Blended learning CPR education program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 26237073

Group type: EXPERIMENTAL
Intervention: Integrated group rehabilitation program
Number of subjects: 41

Group type: COMPARATOR
Intervention: General health orientation about KOA (Control Group)
Number of subjects: 41
Study: 21755368

Group type: EXPERIMENTAL
Intervention: Visual motion cue (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Static cue (Experiment 2)
Number of subjects: 0
Study: 21624304

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human brain natriuretic peptide (rhBNP)
Number of subjects: 2160
Study: 19139364

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) with 0.625 mg conjugated equine estrogens (CEE) with or without 2.5 mg medroxyprogesterone acetate (MPA)
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1403
Study: 16753722

Group type: EXPERIMENTAL
Intervention: Structured learning
Number of subjects: 138

Group type: COMPARATOR
Intervention: Student-directed learning
Number of subjects: 138